These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 31037970

  • 1. Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study.
    Pérez-Belmonte LM, Osuna-Sánchez J, Millán-Gómez M, López-Carmona MD, Gómez-Doblas JJ, Cobos-Palacios L, Sanz-Cánovas J, Barbancho MA, Lara JP, Jiménez-Navarro M, Bernal-López MR, Gómez-Huelgas R.
    Ann Med; 2019; 51(3-4):252-261. PubMed ID: 31037970
    [Abstract] [Full Text] [Related]

  • 2. Glycaemic efficacy and safety of linagliptin compared to a basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: A multicentre randomized clinical trial.
    Vellanki P, Rasouli N, Baldwin D, Alexanian S, Anzola I, Urrutia M, Cardona S, Peng L, Pasquel FJ, Umpierrez GE, Linagliptin Inpatient Research Group.
    Diabetes Obes Metab; 2019 Apr; 21(4):837-843. PubMed ID: 30456796
    [Abstract] [Full Text] [Related]

  • 3. Management of older hospitalized patients with type 2 diabetes using linagliptin: Lina-Older study.
    Pérez-Belmonte LM, Osuna-Sánchez J, Ricci M, Millán-Gómez M, López-Carmona MD, Barbancho MA, Bernal-López MR, Jansen-Chaparro S, Lara JP, Gómez-Huelgas R.
    Panminerva Med; 2023 Mar; 65(1):13-19. PubMed ID: 33880897
    [Abstract] [Full Text] [Related]

  • 4. Simplified glycaemic management for patients with type 2 diabetes admitted for acute decompensated heart failure using linagliptin.
    Pérez-Belmonte LM, Osuna-Sánchez J, Rico-Robles JI, Ricci M, Lara JP, Gómez-Huelgas R.
    Med Clin (Barc); 2022 Feb 25; 158(4):173-177. PubMed ID: 33846004
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
    Zinman B, Ahrén B, Neubacher D, Patel S, Woerle HJ, Johansen OE.
    Can J Diabetes; 2016 Feb 25; 40(1):50-7. PubMed ID: 26474870
    [Abstract] [Full Text] [Related]

  • 6. Use of Linagliptin for the Management of Medicine Department Inpatients with Type 2 Diabetes in Real-World Clinical Practice (Lina-Real-World Study).
    Pérez-Belmonte LM, Gómez-Doblas JJ, Millán-Gómez M, López-Carmona MD, Guijarro-Merino R, Carrasco-Chinchilla F, de Teresa-Galván E, Jiménez-Navarro M, Bernal-López MR, Gómez-Huelgas R.
    J Clin Med; 2018 Sep 11; 7(9):. PubMed ID: 30208631
    [Abstract] [Full Text] [Related]

  • 7. A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Patients With Type 2 Diabetes in Long-term Care and Skilled Nursing Facilities: Linagliptin-LTC Trial.
    Umpierrez GE, Cardona S, Chachkhiani D, Fayfman M, Saiyed S, Wang H, Vellanki P, Haw JS, Olson DE, Pasquel FJ, Johnson TM.
    J Am Med Dir Assoc; 2018 May 11; 19(5):399-404.e3. PubMed ID: 29289540
    [Abstract] [Full Text] [Related]

  • 8. Cofrogliptin once every 2 weeks as add-on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double-blind, non-inferiority trial.
    Ren Q, Li L, Su X, Hu X, Qin G, Han J, Liu Y, Wang J, Ji L.
    Diabetes Obes Metab; 2024 Nov 11; 26(11):5013-5024. PubMed ID: 39308336
    [Abstract] [Full Text] [Related]

  • 9. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
    Guo XH, Feng ZK, Xu LH.
    Zhonghua Nei Ke Za Zhi; 2017 Aug 01; 56(8):588-594. PubMed ID: 28789492
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
    Lajara R, Aguilar R, Hehnke U, Woerle HJ, von Eynatten M.
    Clin Ther; 2014 Nov 01; 36(11):1595-605. PubMed ID: 25236917
    [Abstract] [Full Text] [Related]

  • 11. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
    McGill JB, Yki-Järvinen H, Crowe S, Woerle HJ, von Eynatten M.
    Diab Vasc Dis Res; 2015 Jul 01; 12(4):249-57. PubMed ID: 25941160
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J, Pegelow K, Bramlage P.
    Vasc Health Risk Manag; 2013 Jul 01; 9():711-7. PubMed ID: 24259985
    [Abstract] [Full Text] [Related]

  • 13. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
    Jax T, Stirban A, Terjung A, Esmaeili H, Berk A, Thiemann S, Chilton R, von Eynatten M, Marx N.
    Cardiovasc Diabetol; 2017 Jan 21; 16(1):13. PubMed ID: 28109295
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial.
    Ledesma G, Umpierrez GE, Morley JE, Lewis-D'Agostino D, Keller A, Meinicke T, van der Walt S, von Eynatten M.
    Diabetes Obes Metab; 2019 Nov 21; 21(11):2465-2473. PubMed ID: 31297968
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of sitagliptin with basal-plus insulin regimen versus insulin alone in non-critically ill hospitalized patients with type 2 diabetes: SITA-PLUS hospital trial.
    Gracia-Ramos AE, Cruz-Dominguez MDP, Madrigal-Santillán EO, Rojas-Martínez R, Morales-González JA, Morales-González Á, Hernández-Espinoza M, Vargas-Peñafiel J, Tapia-González MLÁ.
    J Diabetes Complications; 2024 May 21; 38(5):108742. PubMed ID: 38581842
    [Abstract] [Full Text] [Related]

  • 16. A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes.
    Fayfman M, Galindo RJ, Rubin DJ, Mize DL, Anzola I, Urrutia MA, Ramos C, Pasquel FJ, Haw JS, Vellanki P, Wang H, Albury BS, Weaver R, Cardona S, Umpierrez GE.
    Diabetes Care; 2019 Mar 21; 42(3):450-456. PubMed ID: 30679302
    [Abstract] [Full Text] [Related]

  • 17. Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes.
    Inzucchi SE, Nauck MA, Hehnke U, Woerle HJ, von Eynatten M, Henry RR.
    Diabetes Obes Metab; 2015 Sep 21; 17(9):868-77. PubMed ID: 25974030
    [Abstract] [Full Text] [Related]

  • 18. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.
    Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK, CARMELINA® investigators.
    Cardiovasc Diabetol; 2018 Mar 14; 17(1):39. PubMed ID: 29540217
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of Dipeptidyl Peptidase-IV Inhibitor Use in Hospitalized Patients With Diabetes.
    Petite SE, Hill MC.
    Ann Pharmacother; 2021 Nov 14; 55(11):1326-1332. PubMed ID: 33615832
    [Abstract] [Full Text] [Related]

  • 20. Differences in inpatient glycemic control and response to subcutaneous insulin therapy between medicine and surgery patients with type 2 diabetes.
    Smiley D, Umpierrez GE, Hermayer K, Newton C, Jacobs S, Olson DE, Khan A, Rizzo M, Peng L, Reyes D, Cardona S, Fonseca V.
    J Diabetes Complications; 2013 Nov 14; 27(6):637-41. PubMed ID: 23911535
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.